Altered expression of shorter p53 family isoforms can impact melanoma aggressiveness

Cutaneous melanoma is the most aggressive form of skin cancer. Despite the significant advances in the management of melanoma in recent decades, it still represents a challenge for clini-cians. The TP53 gene, the guardian of the genome, which is altered in more than 50% of human cancers, is rarely mutated in melanoma. More recently, researchers started to appreciate the im-portance of shorter p53 isoforms as potential modifiers of the p53‐dependent responses. We ana-lyzed the expression of p53 and p73 isoforms both at the RNA and protein level in a panel of mela-noma‐derived cell lines with different TP53 and BRAF status, in normal conditions or upon treat-ment with common anti‐cancer DNA damaging agents or targeted therapy. Using lentiviral vectors, we also generated stable clones of H1299 p53 null cells over‐expressing the less characterized isoforms Δ160p53α, Δ160p53β, and Δ160p53γ. Further, we obtained two melanoma‐derived cell lines resistant to BRAF inhibitor vemurafenib. We observed that melanoma cell lines expressed a wide array of p53 and p73 isoforms, with Δ160p53α as the most variable one. We demonstrated for the first time that Δ160p53α, and to a lesser extent Δ160p53β, can be recruited on chromatin, and that Δ160p53γ can localize in perinuclear foci; moreover, all Δ160p53 isoforms can stimulate prolif-eration and in vitro migration. Lastly, vemurafenib‐resistant melanoma cells showed an altered expression of p53 and p73 isoforms, namely an increased expression of potentially pro‐oncogenic Δ40p53β and a decrease in tumor‐suppressive TAp73β. We therefore propose that p53 family isoforms can play a role in melanoma cells’ aggressiveness.